Literature DB >> 22226183

The impact of adjunctive iliac stenting on femoral-femoral bypass in contemporary practice.

Chetan P Huded1, Philip P Goodney, Richard J Powell, Brian W Nolan, Eva M Rzucidlo, Samuel T Simone, Daniel B Walsh, David H Stone.   

Abstract

OBJECTIVES: Most reports of femoral-femoral bypass (FFB) were published before the era of endovascular intervention. This study examines the utilization and impact of adjunctive endovascular intervention on FFB in contemporary practice.
METHODS: We reviewed 253 FFB performed in 247 patients between 1984 and 2010. Primary endpoints, including graft patency, primary-assisted patency, limb salvage, and survival, were assessed using Kaplan-Meier life-table analysis. Univariate and multivariate analyses were performed to determine predictors of primary endpoints.
RESULTS: The indication for FFB included claudication (27%; n = 69) and critical limb ischemia (72%; n = 184). Forty-eight patients (19%) were treated urgently for acute ischemia. Mean follow-up was 5.6 ± 5.5 years. Over the study interval, adjunctive iliac percutaneous transluminal angioplasty (PTA)/stent placement increased significantly from 0% to 54% (P trend < .001), while the rate of axillofemoral bypass or no inflow procedure decreased from 100% to 46% (P trend < .001). Despite increased utilization, iliac PTA/stenting was associated with decreased 5-year primary graft patency of 44% compared with 74% for axillofemoral bypass patients and 71% in patients with no adjunctive inflow procedure (P = .004). Patients with inflow iliac PTA/stents also had diminished 5-year assisted primary patency of 61% compared with 85% for axillofemoral bypass patients and 87% in patients without inflow revascularization (P = .002). Adjunctive iliac PTA/stenting did not impact limb salvage or overall survival. Five-year primary patency among claudicants and critical leg ischemia patients was 65% and 68%, respectively.
CONCLUSIONS: The incidence of iliac PTA/stent placement in conjunction with FFB has increased significantly over time in contemporary practice. Reliance on iliac stent placement for FFB inflow is paradoxically associated with both diminished primary and assisted primary graft patency when compared with historical controls. These findings highlight the importance of patient selection and inflow consideration when performing FFB.
Copyright © 2012 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22226183      PMCID: PMC3766718          DOI: 10.1016/j.jvs.2011.10.036

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  20 in total

1.  Role of femorofemoral crossover bypass grafting for unilateral iliac atherosclerotic disease: a comparative evaluation with anatomic bypass.

Authors:  Shinsuke Mii; Daihiko Eguchi; Tomoyoshi Takenaka; Shin-Ichiro Maehara; Shin-Ichi Tomisaki; Hisanobu Sakata
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Transluminal angioplasty of the iliac artery combined with femorofemoral bypass.

Authors:  H S Howell; C H Ingram; A R Parham; I B Miller; W F Harriss; J L Wood; D R Tester
Journal:  South Med J       Date:  1983-01       Impact factor: 0.954

3.  Combined percutaneous transluminal angioplasty, iliac stent deployment, and femorofemoral bypass for bilateral aortoiliac occlusive disease.

Authors:  L A Lopez-Galarza; L I Ray; J Rodriguez-Lopez; E B Diethrich
Journal:  J Am Coll Surg       Date:  1997-03       Impact factor: 6.113

4.  Femorofemoral bypass: appropriate application based on factors affecting outcome.

Authors:  E Criado; M A Farber
Journal:  Semin Vasc Surg       Date:  1997-03       Impact factor: 1.000

Review 5.  Is femorofemoral crossover bypass an option in claudication?

Authors:  Laura Capoccia; Vincent Riambau; Marcio da Rocha
Journal:  Ann Vasc Surg       Date:  2010-08       Impact factor: 1.466

6.  Utility of femorofemoral bypass. Comparison of results with indications for operation.

Authors:  S B Self; J D Richardson; T W Klamer; H W Kaebnick; G E Lambert; R A Mitchell
Journal:  Am Surg       Date:  1991-09       Impact factor: 0.688

7.  Femorofemoral bypass grafts: ten-year experience.

Authors:  F R Plecha; F M Plecha
Journal:  J Vasc Surg       Date:  1984-07       Impact factor: 4.268

8.  Durability of femorofemoral bypass grafting after aortouniiliac endovascular aneurysm repair.

Authors:  Robert J Hinchliffe; Pierre Alric; Peter W Wenham; Brian R Hopkinson
Journal:  J Vasc Surg       Date:  2003-09       Impact factor: 4.268

9.  Femorofemoral bypass: prognostic factors.

Authors:  A N Subram; C O Urrutia-S; D A Ott; D A Cooley
Journal:  Tex Heart Inst J       Date:  1983-09

10.  Hemodynamic and angiographic guidelines in selection of patients for femorofemoral bypass.

Authors:  D P Flanigan; D G Pratt; J J Goodreau; S J Burnham; J S Yao; J J Bergan
Journal:  Arch Surg       Date:  1978-11
View more
  4 in total

1.  Comparison of Direct and Less Invasive Techniques for the Treatment of Severe Aorto-Iliac Occlusive Disease.

Authors:  Kimberly C Zamor; Andrew W Hoel; Irene B Helenowski; Adam W Beck; Joseph R Schneider; Karen J Ho
Journal:  Ann Vasc Surg       Date:  2017-07-21       Impact factor: 1.466

Review 2.  Bypass surgery in limb salvage: inflow procedures.

Authors:  Jean Bismuth; Cassidy Duran
Journal:  Methodist Debakey Cardiovasc J       Date:  2013-04

3.  Axillobifemoral Bypasses: Reappraisal of an Extra-Anatomic Bypass by Analysis of Results and Prognostic Factors.

Authors:  D Dickas; F Verrel; J Kalff; A Koscielny
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 4.  Lower extremity revascularization via endovascular and surgical approaches: A systematic review with emphasis on combined inflow and outflow revascularization.

Authors:  Jihad A Mustapha; Bynthia M Anose; Brad J Martinsen; George Pliagas; Joseph Ricotta; Christopher W Boyes; Michael S Lee; Fadi Saab; George Adams
Journal:  SAGE Open Med       Date:  2020-06-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.